National Comprehensive Cancer Network

Home | About NCCN | Find a Member Institution | Login/Register | Contact Us

Members Only

NCCN Oncology Research Program (ORP)

NCCN ORP Recent News

NCCN ORP Affiliate Research Project

NCCN ORP Scientific Publications

NCCN ORP for Industry

NCCN ORP Investigator Steering Committee

NCCN ORP Testimonials

NCCN Clinical Trials at NCCN Member Institutions

Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions

NCCN Informed Consent Language Database

NCCN Specialized Imaging Research Consortium™ (SIRC)

NCCN ORP Disclosure Policy

NCCN Insights: Analytics, Research & Consulting

NCCN Flash Updates™

NCCN Oncology Insights Reports™

NCCN Oncology Outcomes Database

NCCN Trends™ Surveys & Data

NCCN Trends™ International Surveys

NCCN Collaboration with the National Business Group on Health

Executive Summary

Tool 1: Quick Reference Guide and Assessment

Tool 2: Plan Design and Assessment Tool

Tool 3, Part I: Request for Proposal (RFP) Questions and Requested Evidence for Vendors

Tool 3, Part II: Request for Proposal (RFP) and Response Evaluation for Employers

Tool 3, Part III: RFP and Vendor Scoring

Tool 4: Summary Plan Description (SPD) Guidance

Tool 5: Vendor Contracting and Administration

Tool 6: Evaluation and Plan Reporting

NCCN Resource Tool: REMS

NCCN Virtual Reimbursement Resource Room

NCCN Best Practices

NCCN Health Information Technology Licensees

NCCN Firewall Policy

NCCN Embargo Policy

Read about NCCN Member Institutions in the U.S. News Best Hospitals Guide Ad

Supporter Opportunities

NCCN Research & Business Resources

Multiple Myeloma Guidelines Updated with Numerous Changes to the NCCN Categories of Evidence and Consensus for Induction Therapy Regimens

In the updated NCCN Multiple Myeloma Guidelines, bortezomib plus dexamethasone is now a category 1 option as induction therapy for transplant candidates. This category change from a 2B recommendation is based on updated results of the Intergroupe Francophone du Myelome (IFM) cooperative group phase III trial. Bortezomib, doxorubicin, and dexamethasone is now upgraded to category 1 from a category 2B option, as induction therapy for transplant candidates based on interim data from the HOVON-65/ GMMG-HD4 phase III trial. Bortezomib in combination with thalidomide and dexamethasone is now a category 1 option as induction therapy for transplant candidates. This is based on the updated results of a phase III trial from the GIMEMA Italian Multiple Myeloma Network.

Lenalidomide in combination with dexamethasone is now a category 1 recommendation in the NCCN Guidelines as an induction therapy option for both transplant and non-transplant candidates based on the updated results of the ECOG E4A03 phase III trial.

Older regimens, including dexamethasone as a single agent, thalidomide with dexamethasone for both transplant and non-transplant candidates, DVD (liposomal doxorubicin, vincristine, and dexamethasone) for transplant candidates, and VAD (vincristine, doxorubicin, and dexamethasone) for non-transplant candidates, that were previously category 2A recommendations are now category 2B.